Mostrar registro simples

Can Activation of NRF2 Be a Strategy against COVID-19?

dc.creatorCuadrado, Antonio
dc.creatorPajares, Marta
dc.creatorBenito, Cristina
dc.creatorJiménez-Villegas, José
dc.creatorEscoll, Maribel
dc.creatorFernández-Ginés, Raquel
dc.creatorGarcia Yagüe, Angel J.
dc.creatorLastra, Diego
dc.creatorManda, Gina
dc.creatorRojo, Ana I.
dc.creatorDinkova-Kostova, Albena T.
dc.date.accessioned2020-07-24T22:27:56Z
dc.date.available2020-07-24T22:27:56Z
dc.date.created2020-07-14
dc.identifier.issn0165-6147spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0165614720301656spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11138
dc.format.extent40 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherTrends in Pharmacological Scienceseng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS-CoV-2spa
dc.titleCan Activation of NRF2 Be a Strategy against COVID-19?spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.subject.keywordAnti-inflammatory ARDSspa
dc.subject.keywordBardoxolone methylspa
dc.subject.keywordKEAP1spa
dc.subject.keywordSulforaphanespa
dc.identifier.doihttps://doi.org/10.1016/j.tips.2020.07.003spa
dc.description.abstractenglishAcute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentation. We propose that a multifaceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) can be deployed against the virus. The strategy provides robust cytoprotection by restoring redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19.spa


Arquivos deste item

Thumbnail
Nome:
1-s2.0-S0165614720301656-main.pdf
Tamanho:
3.523Mb
Formato:
PDF
Descrição:
Ver documento
Visualizar/Abrir

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples